Personal information

Russia

Activities

Employment (1)

Federal Research and Clinical Center of Physical-Chemical Medicine: Moscow, MOSCOW, RU

2022-01-01 to present | Deputy Director
Employment
Source: Self-asserted source
Andrey Meshcheryakov

Professional activities (1)

European Society for Medical Oncology: Viganello, TI, CH

Membership
Source: Self-asserted source
Andrey Meshcheryakov

Works (27)

The role of left ventricle global longitudinal srain in prediction of chemotherapy â€”  induced cardiotoxicity in breast cancer patients treated by low and moderate cumulative doses of anthracyclines

Medical alphabet
2023-01-12 | Journal article
Contributors: V. D. Levina; M. G. Poltavskaya; V. P. Sedov; P. Sh. Chomakhidze; L. V. Bolotina; T. I. Deshkina; M. D. Kuklina; A. A. Meshcheryakov; A. G. Komarova; Z. A. Kuli-Zade et al.
Source: check_circle
Crossref

High-sensitivity troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer agents for breast cancer in patients with predominantly low and moderate risk of cardiotoxicity

Russian Journal of Cardiology
2022-12-06 | Journal article
Contributors: V. D. Levina; M. G. Poltavskaya; P. Sh. Chomakhidze; A. A. Meshcheryakov; L. V. Bolotina; T. I. Deshkina; D. S. Valiulina; A. N. Gerasimov; O. V. Andreeva; A. A. Shmeleva et al.
Source: check_circle
Crossref

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

NEJM Evidence
2022-09-10 | Journal article
Part of ISSN: 2766-5526
Contributors: Andrey Meshcheryakov
Source: Self-asserted source
Andrey Meshcheryakov

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

European Journal of Cancer
2022-04 | Journal article
Part of ISSN: 0959-8049
Contributors: Andrey Meshcheryakov
Source: Self-asserted source
Andrey Meshcheryakov

Metastatic gastrointestinal stromal tumor of the greater omentum. Case report

Journal of Modern Oncology
2021-12-15 | Journal article
Contributors: Vladimir V. Yugay; Maxim P. Nikulin; Natalya N. Mazurenko; Valerija V. Mochal'nikova; Dar'ja A. Filonenko; Andrey A. Meshherjakov; Vladislav E. Bugaev; Petr P. Arhiri; Anna M. Stroganova; Ivan S. Stilidi
Source: check_circle
Crossref

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

European Journal of Cancer
2021-11 | Journal article
Part of ISSN: 0959-8049
Contributors: Andrey Meshcheryakov
Source: Self-asserted source
Andrey Meshcheryakov

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

The Lancet Oncology
2021-05 | Journal article
Part of ISSN: 1470-2045
Contributors: Andrey Meshcheryakov
Source: Self-asserted source
Andrey Meshcheryakov

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

The Lancet Oncology
2021-05 | Journal article
Part of ISSN: 1470-2045
Source: Self-asserted source
Andrey Meshcheryakov

Reply to E. Hindié

Journal of Clinical Oncology
2021-03-10 | Journal article
Contributors: Alexander M. M. Eggermont; Christian U. Blank; Mario Mandala; Georgina V. Long; Victoria G. Atkinson; Stéphane Dalle; Andrew M. Haydon; Andrey Meshcheryakov; Adnan Khattak; Matteo S. Carlino et al.
Source: check_circle
Crossref

Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case

Journal of Modern Oncology
2021-02-17 | Journal article
Contributors: Daria A. Filonenko; Bela M. Medvedeva; Andrey A. Meshcheryakov
Source: check_circle
Crossref

Peripheral blood CD8+-lymphocytes populations and its value for direct and outlying treatment results in triple negative breast cancer patients

Immunologiya
2020 | Journal article
Contributors: T.N. Zabotina; A.I. Chertkova; Z.G. Kadagidze; A.A. Borunova; E.K. Shoua; O.O. Gordeeva; A.A. Meshcheryakov
Source: check_circle
Crossref

ASSOCIATION OF NKT- AND ACTIVATED CD25<sup>+</sup> PERIPHERAL BLOOD LYMPHOCYTES WITH DISEASE FREE AND OVERALL SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS

Siberian journal of oncology
2020-12-31 | Journal article
Contributors: A. I. Chertkova; E. G. Slavina; T. N. Zabotina; Z. G. Kadagidze; E. K. Shoua; O. O. Gordeeva; I. V. Kolyadina; L. G. Zhukova; I. P. Gan’shina; A. A. Meshcheryakov
Source: check_circle
Crossref

Combined anti‑HER2 and hormonal treatment in a patient with HR+HER2+ clear‑cell uterine carcinoma: A case report

Molecular and Clinical Oncology
2020-11-27 | Journal article
Contributors: Olga Gordeeva; Lyudmila Meshcheryakova; Apollon Karseladze; Nadezhda Meshcheryakova; Andrey Meshcheryakov
Source: check_circle
Crossref

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Journal of Clinical Oncology
2020-11-20 | Journal article
Part of ISSN: 0732-183X
Part of ISSN: 1527-7755
Contributors: Andrey Meshcheryakov
Source: Self-asserted source
Andrey Meshcheryakov
grade
Preferred source (of 2)‎

Replacing prednisolone with dexamethasone to overcome the resistance to abiraterone in castration-resistant prostate cancer: a clinical case

Cancer Urology
2020-07-22 | Journal article
Contributors: A. A. Meshcheryakov; O. O. Gordeeva
Source: check_circle
Crossref

SDH-deficient gastrointestinal stromal tumors: paradoxical effect of imatinib

Journal of Modern Oncology
2020-07-15 | Journal article
Contributors: Daria A. Filonenko; Andrey A. Meshcheryakov; Petr P. Arkhiri; Maxim P. Nikulin; Evgeniia S. Kolobanova
Source: check_circle
Crossref

Ripretinib (DCC-2618): a new tyrosine kinase inhibitor for the treatment of metastatic gastrointestinal stromal tumors

Russian Journal of Oncology
2020-07-09 | Journal article
Contributors: D.. A Filonenko; T. E. Tikhomirova; A. A. Meshcheryakov
Source: check_circle
Crossref

Successful treatment of a chemo-resistant gestational trophoblastic neoplasia using GEMOX. Clinical case

Russian Journal of Oncology
2020-07-09 | Journal article
Contributors: A. A. Meshcheryakov; T. E. Tikhomirova; L. A. Meshcheryakova
Source: check_circle
Crossref

[Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].

Arkhiv patologii
2019-01-01 | Journal article
Source: Self-asserted source
Andrey Meshcheryakov

Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement.

Future oncology (London, England)
2014-12-01 | Journal article
Source: Self-asserted source
Andrey Meshcheryakov

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

Annals of oncology : official journal of the European Society for Medical Oncology
2012-10-01 | Journal article
Source: Self-asserted source
Andrey Meshcheryakov

Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients.

International journal of cancer
2005-12-01 | Journal article
Source: Self-asserted source
Andrey Meshcheryakov

Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy.

Immunology letters
2005-08-01 | Journal article
Source: Self-asserted source
Andrey Meshcheryakov

[Serological study of a repertoire of human cancer antigens and autoantigens]

Molekuliarnaia biologiia
2004-03-01 | Journal article
Source: Self-asserted source
Andrey Meshcheryakov

Serological identification of antigens associated with renal cell carcinoma.

Russian journal of immunology : RJI : official journal of Russian Society of Immunology
2002-10-01 | Journal article
Source: Self-asserted source
Andrey Meshcheryakov

Human cortactin as putative cancer antigen.

Oncogene
2000-10-01 | Journal article
Source: Self-asserted source
Andrey Meshcheryakov

Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors.

Annals of oncology : official journal of the European Society for Medical Oncology
1993-09-01 | Journal article
PMID: 8240996
Source: Self-asserted source
Andrey Meshcheryakov